ASCO GI 2025 Preview
An Expert’s Guide to the 2025 ASCO Gastrointestinal Cancers Symposium: A Preview of the Top Abstracts

Released: January 21, 2025

Expiration: January 20, 2026

Activity

Progress
1
Course Completed

During the 2025 ASCO Gastrointestinal Cancers Symposium, important results from many clinical trials across gastrointestinal (GI) malignancies will be reported. GI cancer experts Arvind Dasari, MD, MS; Christopher Lieu, MD; and Rachna Shroff, MD, MS, FASCO, have highlighted their most anticipated abstracts, which we will cover online as part of CCO’s Independent Conference Coverage of ASCO GI 2025. Remember to check the CCO website often as the meeting unfolds for downloadable slidesets summarizing the data from these studies and then again for a CME-certified online text module featuring expert analyses and perspectives on the clinical implications of the new data. 

The experts identified the following key studies of interest in colorectal cancers (CRCs) to be reported at ASCO GI 2025.

  • BREAKWATER: data from a randomized phase III trial of first-line of encorafenib plus cetuximab plus chemotherapy vs standard-of-care chemotherapy for BRAF V600E-mutant metastatic CRC. 
  • CheckMate 8HW: randomized phase III data with nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient metastatic CRC. 
  • CAO/ARO/AIO-12 and OPRA pooled analysis: data from 2 trials featuring watch and wait vs total mesorectal excision for patients with rectal cancer with a complete or near-complete response with total neoadjuvant therapy. 
  • Preliminary data from a randomized phase II trial of botensilimab (an anti–CTLA-4 antibody) with or without balstilimab (an anti–PD-1 antibody) for refractory microsatellite stable metastatic CRC without liver metastases. 

The following studies were also noted in neuroendocrine tumors (NETs):

  • STARTER-NET: data from a randomized phase III study of everolimus plus lanreotide vs everolimus monotherapy for unresectable or recurrent gastroenteropancreatic NET.
  • CABINET subgroup analysis: data from a randomized phase III trial of cabozantinib for advanced gastrointestinal NETs after progression on prior therapy. 
  • Data from a matching-adjusted indirect comparison of first-line lutetium Lu 177 dotatate vs sunitinib for advanced grade 2 pancreatic NETs.

The experts also identified the following key studies of interest in hepatobiliary cancers:

  • ACCELERATE: data from a randomized phase III trial of adjuvant chemotherapy vs chemoradiation for gallbladder cancer. 

Remember to Check the CCO Website After ASCO GI 2025!
Revisit the CCO website after the meeting for downloadable slidesets summarizing the data from key studies listed above, along with a comprehensive analysis by our expert faculty members, who will explore the implications of the data in an CME/CNE/ACPE/AAPA-certified text-based module.

Poll

1.

Which of the following presentations are you most looking forward to seeing from ASCO GI 2025?

Submit